EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieLeitlinieOpen Access

Efficacy of Save Medical Corporation (SMC)–01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial

Nicholas Leung iD, Kayo Waki iD, Satoshi Nozoe iD, Shunpei Enomoto iD, Ryo Saito iD, Sakurako Hamagami iD, Toshimasa Yamauchi iD, Masaomi Nangaku iD, Kazuhiko Ohe iD, Yukiko Onishi iD

Journal of Medical Internet Research · 2024

DOI: 10.2196/53740 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Internet Research, 2024. Verfasst von Nicholas Leung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Donald and Barbara Zucker School of Medicine, Hempstead, NY, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Mobile Applications, Self-Management, Smartphone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lifestyle modifications are a key part of type 2 diabetes mellitus treatment. Many patients find long-term self-management difficult, and mobile apps could be a solution. In 2010, in the United States, a mobile app was approved as an official medical device. Similar apps have entered the Japanese market but are yet to be classified as medical devices.

Objective

The objective of this study was to determine the efficacy of Save Medical Corporation (SMC)–01, a mobile app for the support of lifestyle modifications among Japanese patients with type 2 diabetes mellitus.

Methods

This was a 24-week multi-institutional, prospective randomized controlled trial. The intervention group received SMC-01, an app with functions allowing patients to record data and receive personalized feedback to encourage a healthier lifestyle. The control group used paper journals for diabetes self-management. The primary outcome was the between-group difference in change in hemoglobin A1c from baseline to week 12.

Results

The change in hemoglobin A1c from baseline to week 12 was –0.05% (95% CI –0.14% to 0.04%) in the intervention group and 0.06% (95% CI –0.04% to 0.15%) in the control group. The between-group difference in change was –0.11% (95% CI –0.24% to 0.03%; P=.11).

Conclusions

There was no statistically significant change in glycemic control. The lack of change could be due to SMC-01 insufficiently inducing behavior change, absence of screening for patients who have high intention to change their lifestyle, low effective usage of SMC-01 due to design issues, or problems with the SMC-01 intervention. Future efforts should focus on these issues in the early phase of developing interventions. Trial Registration Japan Registry of Clinical Trials jRCT2032200033; https://jrct.niph.go.jp/latest-detail/jRCT2032200033

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Mobile ApplicationsSelf-ManagementSmartphonePractice Guidelines as TopicAgedFemaleHumansMaleMiddle AgedGlycated HemoglobinJapanProspective Studies

Stichwörter der Autor:innen

HbA1cJapanRCTRCTsT2DMapp developmentbehavioral changediabetesdiabetes mellitusefficacyhemoglobin A1cmHealthmobile appmobile appsmobile phone

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Donald and Barbara Zucker School of Medicine, Hempstead, NY, United States.
  • Department of Planning, Information and Management, University of Tokyo Hospital, Tokyo, Japan.
  • Department of Biomedical Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Save Medical Corporation, Tokyo, Japan.
  • Faculty of Biology, University of Cambridge, Cambridge, United Kingdom.

ORCID-Profile: Nicholas Leung, Kayo Waki, Satoshi Nozoe, Shunpei Enomoto, Ryo Saito, Sakurako Hamagami, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Yukiko Onishi

Zitieren

APA

Leung, N., Waki, K., Nozoe, S., Enomoto, S., Saito, R., Hamagami, S., Yamauchi, T., Nangaku, M., Ohe, K., & Onishi, Y. (2024). Efficacy of Save Medical Corporation (SMC)–01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial. Journal of Medical Internet Research. https://doi.org/10.2196/53740

Vancouver

Leung N, Waki K, Nozoe S, Enomoto S, Saito R, Hamagami S, et al. Efficacy of Save Medical Corporation (SMC)–01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial. Journal of Medical Internet Research. 2024. doi:10.2196/53740

BibTeX
@article{Leung2024,
  author = {Leung, Nicholas and Waki, Kayo and Nozoe, Satoshi and Enomoto, Shunpei and Saito, Ryo and Hamagami, Sakurako and Yamauchi, Toshimasa and Nangaku, Masaomi and Ohe, Kazuhiko and Onishi, Yukiko},
  title = {Efficacy of Save Medical Corporation (SMC)–01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial},
  journal = {Journal of Medical Internet Research},
  year = {2024},
  doi = {10.2196/53740}
}
Kostenlos starten →